Liver immune-related adverse effects of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: A propensity score matched study with competing risk analyses
Zhou, J, Chau, Y-L A, Yoo, J W, Lee, S, Ng, K, Dee, E C, Liu, T, Wai, A K C, Zhang, Q and Tse, G 2022. Liver immune-related adverse effects of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: A propensity score matched study with competing risk analyses. Clinical Oncology (Royal College of Radiologists (Great Britain)). https://doi.org/10.1016/j.clon.2022.03.006
|Authors||Zhou, J, Chau, Y-L A, Yoo, J W, Lee, S, Ng, K, Dee, E C, Liu, T, Wai, A K C, Zhang, Q and Tse, G|
Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors, major classes of immune checkpoint inhibitors, are increasingly prescribed for different cancers. Data from Asian cohorts have been sparse , especially on the liver immune-related adverse effects . We examined patients receiving PD-1 or PD-L1 inhibitors until 31 August 2020 in Hong Kong. The methods are detailed in Supplementary Methods. A list of PD-1 and PD-L1 drugs and ICD-9 codes are listed in Supplementary Tables S1 and S2, respectively. Propensity score matching between PD-1 and PD-L1 inhibitor users (1:3) with nearest neighbour search strategy was carried out. Initially, 2426 cancer patients were identified (Supplementary Figure S1). After exclusion, 1735 patients were included (64.78% males, median age 63.5 years old; PD-1 inhibitors: n = 1341, PD-L1 inhibitors: n = 394) (Supplementary Table S3). On follow-up (median: 262 days), 1120 patients died (64.5%) and 33 patients showed grade 3/4 hepatitis (1.90%) after PD-1/PD-L1 inhibitor treatment. In the matched cohort, PD-L1 inhibitor use was associated with higher rates of all-cause mortality (hazard ratio 1.20, P = 0.0149) and grade 3/4 hepatitis (hazard ratio 3.53, P = 0.0044) compared with PD-1 inhibitor use (Supplementary Table S4).
A previous study found that incidence of severe hepatitis was 8.6% in combination therapy using nivolumab and ipilimumab and 1% in monotherapy with either drug individually . Another study found a higher incidence of 10.1% . In our study, the incidence of severe hepatitis was lower. A possible explanation is that prior studies included patients with pre-existing grade 1 or 2 hepatitis , which were excluded in this study. Together, the incidence of grade 3/4 hepatitis was 1.9% after PD-1/PD-L1 inhibitor treatment. PD-L1 inhibitor use was associated with a higher risk of grade 3/4 hepatitis compared with PD-1 inhibitor use after propensity score matching.
|Keywords||Cell death; Oncology; Cancer|
|Journal||Clinical Oncology (Royal College of Radiologists (Great Britain))|
|Digital Object Identifier (DOI)||https://doi.org/10.1016/j.clon.2022.03.006|
|Online||20 Mar 2022|
|Publication process dates|
|Accepted||04 Mar 2022|
|Deposited||11 Apr 2022|
|Accepted author manuscript|
Accepted author manuscript
4views this month
0downloads this month